Clinical Trial Update: Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis [NA]

View source ↗

Summary

A Mayo Clinic-sponsored study evaluating muromonab-CD3 in combination with cyclosporine for giant cell myocarditis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Myocarditis
• Myocarditis

Drugs mentioned

• NEORAL (CYCLOSPORINE)
• Orthoclone OKT3 (muromonab-CD3)

Snippet

Sponsor: Mayo Clinic | Conditions: Myocarditis | NA | Status: COMPLETED